Qualigen Therapeutics, Inc. (QLGN)

NASDAQ: QLGN · IEX Real-Time Price · USD

0.272

-0.021 (-7.10%)

At close: Jul 22, 2024, 9:12 AM

0.265

-0.007 (-2.68%)

Pre-market: Jul 22, 2024, 9:21 AM EDT

Qualigen Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Mar 31, 2020	Dec 31, 2019	2018 - 2013
Net Income	-11.6	-13.42	-18.64	-17.9	-1.79	-10.13	Upgrade
Depreciation & Amortization	-0.11	0	0.01	0.34	0.22	0.11	Upgrade
Share-Based Compensation	0.9	1.1	4.77	5.29	0.01	0.44	Upgrade
Other Operating Activities	2.36	2.01	0.62	-2.47	1.62	-4.93	Upgrade
Operating Cash Flow	-8.45	-10.3	-13.25	-14.73	0.06	-14.52	Upgrade
Capital Expenditures	0.2	0	0	-0.13	-0.01	-0	Upgrade
Change in Investments	0	0	0	0	0	7	Upgrade
Other Investing Activities	4.22	4.22	-0.18	-0.01	-0.19	-	Upgrade
Investing Cash Flow	4.41	4.22	-0.18	-0.14	-0.19	7	Upgrade
Share Issuance / Repurchase	0	0	-0	8.82	0	1.41	Upgrade
Debt Issued / Paid	-0.08	-0.55	2.9	-0.14	0.17	0	Upgrade
Other Financing Activities	-	-	0.01	-0.25	-	-	Upgrade
Financing Cash Flow	-0.08	-0.55	2.91	8.43	0.17	1.41	Upgrade
Exchange Rate Effect	-0.16	0	0.02	0	0	0	Upgrade
Net Cash Flow	-4.11	-6.64	-10.52	-6.44	0.03	-6.11	Upgrade
Free Cash Flow	-8.26	-10.3	-13.25	-14.87	0.05	-14.52	Upgrade
Free Cash Flow Margin	-507.41%	-	-	-262.93%	0.91%	-	Upgrade
Free Cash Flow Per Share	-1.39	-2.03	-3.45	-5.07	0.09	-379.26	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).